Prikkelbare darmsyndroom

Onderwerpen met wetenschappelijke, medische of algemene gezondheidsgerelateerde informatie en discussie dat niet specifiek betrekking heeft op de ziekte van Lyme.
Gebruikersavatar
vonneke
Berichten: 7127
Lid geworden op: Do 16 Jun 2005 20:57

Prikkelbare darmsyndroom

Berichtdoor vonneke » Wo 5 Mei 2010 16:24

Antibiotic Prevents IBS Symptoms For Weeks After Final Dose :

http://www.medicalnewstoday.com/articles/187610.php




IBS = Prikkelbare darmsyndroom : http://nl.wikipedia.org/wiki/Prikkelbare-darmsyndroom
Laatst gewijzigd door vonneke op Ma 26 Jul 2010 15:06, 1 keer totaal gewijzigd.

Je zelfbeeld bepaalt vaak de grenzen
van wat je als individu kunt bereiken.


Afbeelding

Gebruikersavatar
vonneke
Berichten: 7127
Lid geworden op: Do 16 Jun 2005 20:57

Re: Antibiotic Prevents IBS Symptoms For Weeks After Final D

Berichtdoor vonneke » Wo 5 Mei 2010 16:30

Bij wikipedia lees ik dat bij de diagnose IBS die ik jaren geleden van de internist kreeg de volgende symptomen niet voor mogen komen :

Verder mogen de volgende symptomen niet voorkomen:

-bloed in de ontlasting
-gewichtsverlies
-koorts
-fysieke afwijkingen

Vreemd want 3 van die symptomen had ik sowieso toen ik er voor onderzoek kwam en had toen net in korte tijd 13 kilo gewichtsverlies.


Qua darmen had ik bij alle AB kuren baat , alleen bij minocycline kreeg ik problemen met de maag.

Je zelfbeeld bepaalt vaak de grenzen
van wat je als individu kunt bereiken.


Afbeelding

Gebruikersavatar
vonneke
Berichten: 7127
Lid geworden op: Do 16 Jun 2005 20:57

Re: Prikkelbare darmsyndroom

Berichtdoor vonneke » Ma 26 Jul 2010 15:08

http://www.medicalnewstoday.com/articles/195624.php

Study Finds Structural Brain Alterations In Patients With Irritable Bowel Syndrome

A large academic study has demonstrated structural changes in specific brain regions in female patients with irritable bowel syndrome (IBS), a condition that causes pain and discomfort in the abdomen, along with diarrhea, constipation or both.

A collaborative effort between UCLA and Canada's McGill University, the study appears in the July issue of the journal Gastroenterology.

The findings show that IBS is associated with both decreases and increases in grey matter density in key areas of the brain involved in attention, emotion regulation, pain inhibition and the processing of visceral information.

IBS affects approximately 15 percent of the U.S. population, primarily women. Currently, the condition is considered by the medical field to be a "functional" syndrome of the digestive tract not working properly rather than an "organic" disorder with structural organ changes. Efforts to identify structural or biochemical alterations in the gut have largely been unsuccessful. Even though the pathophysiology is not completely understood, it is generally agreed that IBS represents an alteration in brain-gut interactions.

These study findings, however, show actual structural changes to the brain, which places IBS in the category of other pain disorders, such as lower back pain, temporomandibular joint disorder, migraines and hip pain conditions in which some of the same anatomical brain changes have been observed, as well as other changes. A recent, smaller study suggested structural brain changes in IBS, but a larger definitive study hadn't been completed until now.

"Discovering structural changes in the brain, whether they are primary or secondary to the gastrointestinal symptoms, demonstrates an 'organic' component to IBS and supports the concept of a brain-gut disorder," said study author Dr. Emeran Mayer, professor of medicine, physiology and psychiatry at the David Geffen School of Medicine at UCLA. "Also, the finding removes the idea once and for all that IBS symptoms are not real and are 'only psychological.' The findings will give us more insight into better understanding IBS."

Researchers employed imaging techniques to examine and analyze brain anatomical differences between 55 female IBS patients and 48 female control subjects. Patients had moderate IBS severity, with disease duration from one to 34 years (average 11 years). The average age of the participants was 31.

Investigators found both increases and decreases of brain grey matter in specific cortical brain regions

Even after accounting for additional factors such as anxiety and depression, researchers still discovered differences between IBS patients and control subjects in areas of the brain involved in cognitive and evaluative functions, including the prefrontal and posterior parietal cortices, and in the posterior insula, which represents the primary viscerosensory cortex receiving sensory information from the gastrointestinal tract.

"The grey-matter changes in the posterior insula are particularly interesting since they may play a role in central pain amplification for IBS patients," said study author David A. Seminowicz, Ph.D., of the Alan Edwards Centre for Research on Pain at McGill University. "This particular finding may point to a specific brain difference or abnormality that plays a role in heightening pain signals that reach the brain from the gut."

Decreases in grey matter in IBS patients occurred in several regions involved in attentional brain processes, which decide what the body should pay attention to. The thalamus and midbrain also showed reductions, including a region the periaqueductal grey that plays a major role in suppressing pain.

"Reductions of grey matter in these key areas may demonstrate an inability of the brain to effectively inhibit pain responses," Seminowicz said.

The observed decreases in brain grey matter were consistent across IBS patient sub-groups, such as those experiencing more diarrhea-like symptoms than constipation.

"We noticed that the structural brain changes varied between patients who characterized their symptoms primarily as pain, rather than non-painful discomfort," said Mayer, director of the UCLA Center for Neurobiology of Stress. "In contrast, the length of time a patient has had IBS was not related to these structural brain changes."

Mayer added that the next steps in the research will include exploring whether genes can be identified that are related to these structural brain changes. In addition, there is a need to increase the study sample size to address male-female differences and to determine if these brain changes are a cause or consequence of having IBS.

The study was funded by the National Institutes of Health

Je zelfbeeld bepaalt vaak de grenzen
van wat je als individu kunt bereiken.


Afbeelding

Juul
Berichten: 496
Lid geworden op: Wo 9 Jul 2008 17:40

Re: Antibiotic Prevents IBS Symptoms For Weeks After Final D

Berichtdoor Juul » Ma 26 Jul 2010 17:59

-
Laatst gewijzigd door Juul op Zo 28 Sep 2014 20:54, 1 keer totaal gewijzigd.

eus
Berichten: 1012
Lid geworden op: Vr 15 Jan 2010 13:49

Re: Prikkelbare darmsyndroom

Berichtdoor eus » Ma 26 Jul 2010 19:29

Mijn internist noemde IBS "een verlegenheidsdiagnose".
De overwinning is
niet altijd voor de snelsten,
of de sterksten,
maar voor hen die volhouden

beagle
Berichten: 47
Lid geworden op: Vr 26 Mar 2010 21:12

Re: Prikkelbare darmsyndroom

Berichtdoor beagle » Di 3 Aug 2010 10:11

PDS is idd een diagnose die ze stellen, als ze het eigenlijk (nog) niet weten.
Bij mij werd er gezegd PDS, maar je bloedwaarden zijn niet consistent...
m.a.w. Het beessie moet een naam hebben, maar het is het niet.

Ondertussen wel al meer dan anderhalf jaar aan de Movicolon.
Dit om in iedergeval ontlasting kwijt te kunnen :?
carpe diem

Gebruikersavatar
vonneke
Berichten: 7127
Lid geworden op: Do 16 Jun 2005 20:57

Re: Prikkelbare darmsyndroom

Berichtdoor vonneke » Zo 8 Aug 2010 14:28

http://www.medicalnewstoday.com/articles/196744.php

Scientists Target Possible Cause Of One Form Of Bowel Disease

A possible cause of irritable bowel syndrome has been traced to a small piece of RNA that blocks a substance protecting the colon membrane, leading to hostile conditions that can produce diarrhea, bloating and chronic abdominal pain.

New research shows that this RNA segment sends signals that stop the activity of the gene that produces glutamine, an amino acid. Previous research has linked a shortage of glutamine in the gut with the seepage of toxins and bacteria through the intestinal wall, irritating nerves and creating disease symptoms.

Scientists say that trying to generate glutamine in the disordered bowel by silencing this RNA segment could open up a whole new way of thinking about treating the diarrhea-predominant type of irritable bowel syndrome (IBS). In the meantime, they are making plans to conduct a clinical trial to see if glutamine supplements could also reduce common IBS symptoms

This form of the disorder is characterized by diarrhea and bloating as well as chronic abdominal pain that is difficult to treat. About a third of IBS patients have the diarrhea-predominant type, another third experience consistent constipation, and the rest experience alternating bouts of diarrhea and constipation.

In the Ohio State University study, researchers observed that in human tissue samples, the presence of this small piece of RNA was associated with reduced activity by the gene that produces glutamine. Lower levels of glutamine were seen only in tissue samples from patients with the diarrhea-predominant type of IBS.

A group of these patients also had a condition called increased intestinal permeability, which allows toxins and bacteria into the colon that typically can't get in. The resulting irritation to nerves in the colon is believed to contribute to diarrhea and abdominal pain. The finding suggests that the glutamine deficiency is connected to the increased intestinal permeability, which dramatically increases the likelihood that diarrhea-predominant IBS symptoms will follow The researchers say that manipulating that tiny piece of RNA, known as microRNA-29a, has potential as a novel treatment for IBS. "We've known about characteristics of this disease, but we didn't know the reasons behind them. This study helps us connect everything together. Maybe if we can modulate the microRNA, we can heal the disease. That is our whole hypothesis," said QiQi Zhou, assistant professor of internal medicine at Ohio State and lead author of the study.

The research is published in a recent issue of the journal Gut.

While testing the effectiveness of glutamine supplementation in IBS patients could lead to a viable treatment for symptoms, the researchers say it is important to continue to pursue the underlying cause of IBS

"We treat the disorder, but we still don't understand it completely," said study senior co-author G. Nicholas Verne, professor of internal medicine and director of the Division of Gastroenterology, Hepatology and Nutrition at Ohio State. "We often have to use multiple therapies to attack the symptoms, but the pain is by far the most difficult to treat. For some patients, the pain responds only to escalating doses of narcotics or tricyclic antidepressants.

"That's why if we had a specific target for an underlying structural defect, we could try to resolve that defect as a much more effective way to reduce the symptoms."

Zhou, Verne and colleagues are the first group of scientists to report on a link between microRNAs, glutamine deficiency and IBS. Most studies of microRNAs have identified their role in the development of cancer.

RNA in cells is responsible for using instructions carried in the DNA to make proteins, but microRNAs are small segments of RNA that, when they become overactive themselves, can block the protein-building process. Each microRNA can target numerous genes, but Zhou concentrated on microRNA-29a and its connection to the production of glutamine in this study because of glutamine's established connection to intestinal permeability.

The researchers collected intestinal tissue and blood samples from three groups: IBS patients with increased intestinal permeability, IBS patients with normal intestinal permeability and control participants with no bowel disease.

The samples showed that microRNA-29a levels were four times higher in the tissues of IBS patients with increased intestinal permeability than were levels seen in IBS patients with normal intestinal permeability conditions and in participants with no bowel disease.

The scientists further tested this relationship by manipulating the microRNA-29a in experiments. When the microRNA-29a levels were driven up, the function of the gene that produces glutamine was prevented and intestinal membrane permeability increased, as well. When the microRNA-29a was artificially silenced, gene function was active, glutamine was produced and the intestinal membrane permeability was closer to normal.

"We've only tested the one target gene, and we've shown that when the gene activity is low, or the gene is not expressed, that's when disease characteristics come into play," Zhou said. "But there still may be other target genes related to this process."

The study also sought to determine how much related genetic information was contained in blood microvesicles, which are tiny blood vessel membrane fragments. Because the heightened expression of microRNA-29a was also detected in microvesicles from IBS patients with increased permeability in this study, the scientists believe a specially handled blood sample could provide as much disease information as a tissue sample for diagnostic purposes.


Je zelfbeeld bepaalt vaak de grenzen
van wat je als individu kunt bereiken.


Afbeelding

Gebruikersavatar
vonneke
Berichten: 7127
Lid geworden op: Do 16 Jun 2005 20:57

Re: Prikkelbare darmsyndroom

Berichtdoor vonneke » Zo 22 Aug 2010 15:07

Proof That Irritable Bowel Syndrome Is Not In Your Head :

http://www.medicalnewstoday.com/articles/198444.php

Je zelfbeeld bepaalt vaak de grenzen
van wat je als individu kunt bereiken.


Afbeelding

Gebruikersavatar
vonneke
Berichten: 7127
Lid geworden op: Do 16 Jun 2005 20:57

Re: Prikkelbare darmsyndroom

Berichtdoor vonneke » Wo 28 Dec 2011 11:18

http://www.ntvg.nl/publicatie/Lichaamsb ... m/volledig

Ned Tijdschr Geneeskd. 2011;155:C835

Lichaamsbeweging vermindert prikkelbaredarmsyndroom

Zelfs een lichte verhoging in de mate van lichamelijke activiteit kan de klachten van patiënten met het prikkelbaredarmsyndroom (PDS) verminderen. Dat suggereert een studie van Elisabet Johannesson en collega’s van de universiteit van Götenburg (Zweden) gepubliceerd in The American Journal of Gastroenterology (2011; doi:10.1038/ajg.2010.480). De studie is het eerste gerandomiseerde onderzoek naar het effect van beweging bij PDS.

Ook nu al wordt PDS-patiënten vaak aangeraden om actiever te worden, maar het was nog niet goed onderzocht of beweging ook daadwerkelijk een gunstig effect heeft op de aandoening. Johannesson en collega’s probeerden dit duidelijk te krijgen door 102 patiënten te verdelen tussen een groep die werd gestimuleerd om gedurende 12 weken meer te bewegen en een groep die werd aangeraden het huidige activiteitenniveau te handhaven. De patiënten die werden aangezet om te bewegen, kregen één of twee keer per maand telefonisch advies over bewegen van een fysiotherapeut en vulden dagelijks een trainingsdagboek in. Verder werd hun conditie na zes weken getest met behulp van een fietstest.

Aan het einde van de studie waren de PDS-symptomen in de groep die meer was gaan bewegen sterker verbeterd dan in de controlegroep (-51 vs. -5 op de IBS-schaal voor PDS-symptomen). Daarbij waren er in de controlegroep meer patiënten bij wie de ziekte was verergerd dan in de groep die actiever was geworden.

Het onderzoek suggereert dat het risico op verslechtering van de symptomen groter is bij inactieve patiënten, schrijven Johannesson en collega’s. Een belangrijke boodschap aan patiënten moet dan ook zijn dat hun klachten mogelijk verergeren als zij inactief blijven, stellen de onderzoekers. Lichaamsbeweging moet de primaire behandeling voor PDS vormen, is hun conclusie.

Je zelfbeeld bepaalt vaak de grenzen
van wat je als individu kunt bereiken.


Afbeelding


Terug naar “Gezondheid Algemeen”

Wie is er online

Gebruikers op dit forum: Common Crawl [ Bot] en 0 gasten